60388-36-5

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-(trifluoromethyl)benzothiazol-2-amine is utilized as a building block for the synthesis of novel pharmaceuticals, particularly for the development of drugs that target specific biological pathways or enzymes. Its unique chemical structure and reactive properties make it a promising candidate for creating new therapeutic agents.
Used in Materials Science:
In the field of materials science, 4-(trifluoromethyl)benzothiazol-2-amine may be employed to develop new materials with specific properties, leveraging its chemical structure and reactivity.
Used in Organic Synthesis:
4-(trifluoromethyl)benzothiazol-2-amine also has applications in organic synthesis, where it can be used to create a variety of organic compounds, taking advantage of its unique chemical characteristics to form new molecules with potential applications in various industries.

InChI:InChI=1/C8H5F3N2S/c9-8(10,11)4-2-1-3-5-6(4)13-7(12)14-5/h1-3H,(H2,12,13)

Upstream product

• 88-17-5 2-(trifluoromethyl)benzenamine 
• 1147550-11-5 ammonium thiocyanate 
• 1736-71-6 2-trifluoromethylphenyl thiourea 

Downstream Products

• 131106-69-9 4-(trifluoromethyl)benzothiazole 

Relevant academic research and scientific papers

Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives Containing Benzo[d]thiazole-2-yl Urea as c-Met Kinase Inhibitors

A series of novel 4-phenoxyquinoline derivatives containing the benzo[d]thiazole-2-yl urea moiety were synthesized and evaluated for their cytotoxicity against the HT-29, MKN-45, and H460 cell lines. The structures of the target compounds were confirmed by 1H NMR and MS spectra. Most of them showed moderate to excellent potency against the three tested cell lines. Especially, compound 23 was identified a promising agent (c-Met IC50 = 17.6 nM), showing the most potent anticancer activities with IC50 values of 0.18, 0.06, and 0.01 μM against the HT-29, MKN-45, and H460 cell lines, respectively. The docking results of 23 with the c-Met kinase model 3LQ8 showed a specific binding mode between the ligand and the target protein.

Substituted 2-benzothiazolamines as sodium flux inhibitors: Quantitative structure-activity relationships and anticonvulsant activity

Thirty-two aryl-substituted 2-benzothiazolamines have been tested for their ability to modulate sodium flux in rat cortical slices. A QSAR analysis, applied to these derivatives, showed a trend toward increasing potency as sodium flux inhibitors with increasing lipophilicity, decreasing size, and increasing electron withdrawal of the benzo ring substitutents. Additionally, 4- or 5-substitution of the benzo ring was found to decrease potency. The combination of increased lipophilicity, small size, and electron withdrawal severely limited which groups were tolerated on the benzo ring, thus suggesting that the optimal substitution patterns have been prepared within this series. Nine of these compounds were potent inhibitors of veratridine-induced sodium flux (NaFl). These nine compounds also proved to be anticonvulsant in the maximal electroshock (MES) assay. Fourteen additional 2-benzothiazolamines demonstrated activity in the MES screen, yet exhibited no activity in the NaFl assay. These derivatives may be interacting at the sodium channel in a manner not discernible by the flux paradigm, or they may be acting by an alternative mechanism in vivo.

Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents

A series of substituted 2-aminobenzothiazoles and derivatives useful for treating cerebrovascular disorders are disclosed. Also disclosed is a new method for treating such disorders.